Please ensure Javascript is enabled for purposes of website accessibility

3 Reasons to Buy Vertex Pharmaceuticals Stock Right Now

By Prosper Junior Bakiny - May 8, 2020 at 6:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Vertex Pharmaceuticals’ stock has been providing market-beating returns of late. Here’s why it can continue outperforming.

Vertex Pharmaceuticals (VRTX 0.81%), a biotech company that holds a monopoly in the market for drugs that treat cystic fibrosis (CF), reported strong first quarter results on April 29. During the quarter, Vertex recorded net revenue of $1.5 billion, representing a whopping 77% year-over-year increase.

Further, Vertex's net income based on generally accepted accounting principles (GAAP) was $603 million, a 124% increase compared to the prior-year quarter. Vertex's stock got a nice boost after its most recent quarterly update, and year to date, the company's shares are up by 22.8%. And even though the company is currently trading at about 33 times future earnings, there are good reasons to consider buying its shares. Here are three of those reasons.

Hand drawing an upward pointing graph.

Image Source: Getty Images.

1. Trikafta is already successful

Vertex's first treatment for the underlying causes of CF was approved back in 2012. However, its most crucial approval yet came in October 2019 when the U.S. Food and Drug Administration (FDA) gave the green light to Trikafta. Why was this approval so important?

Since there are many mutations that cause CF, Vertex's drugs can only treat a limited number of CF patients. But Trikafta was developed to treat patients with the most common CF mutation. Thanks to this drug, Vertex can now treat about 90% of patients with CF, which makes up about 68,000 of the 75,000 CF patients in the U.S., Europe, and Australia.

Trikafta is already making significant headway. During Vertex's first quarter, revenue from Trikafta was $895 million. Note that Vertex's other three products recorded a total revenue of $620 million during the quarter. In other words, Trikafta was responsible for Vertex's stellar revenue growth during the first quarter, and given that this product has been approved for less than a year, it likely still has a lot of room to grow.

2. Vertex revises its guidance

Impressive revenue and earnings growth wasn't the only good news in Vertex's latest quarterly update. The company also announced that it was adjusting its guidance for the current fiscal year. And while many companies are slashing or outright withdrawing their initial revenue and earnings prediction for 2020 due to the ongoing pandemic, Vertex revised its guidance upward for the year.

The company previously expected its revenue for the fiscal year to be between $5.1 billion and $5.3 billion. Now, Vertex expects its revenue for 2020 to be between $5.3 billion and $5.6 billion. The midpoint of this guidance would represent a year-over-year increase of about 31%. In short, Vertex will continue to thrive even in the current uncertain economic landscape. 

3. Exciting opportunities 

Vertex is looking beyond the CF market to find other growth opportunities. Two of these opportunities are worth mentioning. First, the biotech acquired privately held Semma Therapeutics last year in an all-cash transaction valued at $950 million.

Semma is going after a challenging target: The company is looking to cure type 1 diabetes. And now that Semma is under Vertex's umbrella, Vertex could profit immensely from this project; that is, if it ever comes to fruition. Sure, it sounds like a long shot at this point, but Vertex isn't content with its dominance in the CF market. 

Second, Vertex could benefit from its collaboration with CRISPR Therapeutics (CRSP 1.55%). The two companies are developing several exciting candidates together, the most notable being CTX001, which showed strong potential in the treatment of sickle cell disease and transfusion-dependent beta thalassemia, both of which are rare blood disorders. CTX001 is still the early testing phases, but it is yet another interesting potential product which could be a significant growth driver for Vertex -- if it ever earns FDA approval. 

Investor takeaway

Vertex's latest approval is already making significant headway. Also, the company's revenue and earnings aren't taking a hit as a result of the ongoing pandemic. Lastly, the biotech company has several growth opportunities at its disposal. For all those reasons, Vertex still looks like a biotech stock worth buying today.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends CRISPR Therapeutics. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$294.52 (0.81%) $2.36
CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
CRSP
$78.66 (1.55%) $1.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.